We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · January 24, 2020

Safety of JAK inhibitors in Patients With IBD and Other Immune Diseases

Gastroenterology

 

Additional Info

Gastroenterology
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-Mediated Diseases: A Systematic Review and Meta-Analysis
Gastroenterology 2020 Jan 08;[EPub Ahead of Print], P Olivera, J Lasa, S Bonovas, et al

Further Reading